Telomir Pharmaceuticals, Inc. (TELO)
0.88
+0.10
(+12.81%)
USD |
NASDAQ |
Nov 06, 10:34
Telomir Pharmaceuticals Net Income (Quarterly) : -1.722M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.722M |
| March 31, 2026 | -0.9909M |
| December 31, 2025 | -2.061M |
| September 30, 2025 | -1.102M |
| June 30, 2025 | -5.070M |
| March 31, 2025 | -2.180M |
| December 31, 2024 | -2.898M |
| September 30, 2024 | -5.991M |
| June 30, 2024 | -1.449M |
| Date | Value |
|---|---|
| March 31, 2024 | -6.255M |
| December 31, 2023 | -9.327M |
| September 30, 2023 | -1.711M |
| June 30, 2023 | -1.550M |
| March 31, 2023 | -0.4829M |
| December 31, 2022 | -0.4871M |
| September 30, 2022 | -0.2335M |
| June 30, 2022 | -0.0701M |
| March 31, 2022 | -0.0635M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.722M |
| EPS Diluted (Quarterly) | -0.7863 |
| Enterprise Value | 48.62M |
| Earnings Yield | -103.3% |
| Normalized Earnings Yield | -103.31 |